2022 / 04

Next Paper
DOI: 10.24075/brsmu.2022.039

ORIGINAL RESEARCH

Content of CD4+ cells expressing CD39/CD73 ectonucleotidases in children with inflammatory bowel diseases

Radygina TV1, Petrichuk SV1, Kuptsova DG1, Potapov AS1,2, Illarionov AS2, Anushenko AO1, Kurbatova OV1, Semikina EL1,2
About authors

1 National Medical Research Center for Children's Health, Moscow, Russia

2 Sechenov First Moscow State Medical University, Moscow, Russia

Correspondence should be addressed: Tatiana V. Radygina
Lomonosovsky prospekt, 2/1, Moscow, 119296, Russia; ur.liam@anigidarvt

About paper

Funding: the study was carried out on state assignment of the Ministry of Health of Russia, number АААА-А19-119013090093-2.

Acknowledgement: the authors thank all patients for participation and acknowledge the Gastroenterology Department with Hepatology Group of the National Medical Research Center for Children's Health and its collaboration.

Compliance with ethical standards: the study was approved by the Ethics Committee of the National Medical Research Center for Children's Health, Moscow (protocol № 6 dated June 11, 2019). The informed consent was submitted by all study participants.

Received: 2022-06-22 Accepted: 2022-07-16 Published online: 2022-07-31
|
  1. Burisch J, Pedersen N, Сukoviс-Сavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCOEpiCom inception cohort. Gut. 2014; 63 (4): 588–97.
  2. Benchimol EI, Guttmann A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut. 2009; 58: 1490–7.
  3. Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse, Inflamm. Bowel Dis. 2015; 21: 182–97.
  4. Kniazev OV, Shkurko TV, Kagramanova AV, Veselov AV, Nikonov EL. Epidemiology of inflammatory bowel disease. State of the problem (review). Russian Journal of Evidence-Based Gastroenterology. 2020; 9 (2): 66–73. Russian.
  5. Yan JB, Luo MM, Chen ZY, He BH. The function and role of the Th17/Treg cell balance in Inflammatory bowel disease. J Immunol Res. 2020; 2020: 8813558. DOI: 10.1155/2020/8813558.
  6. Petrichuk SV, Miroshkina LV, Semikina EL, Toptygina AP, Potapov AS, Tsimbalova EG, et al. Indicators of the lymphocyte subsets as efficiciency predictors of therapy with inhibitors of TNFα in children with inflammatory bowel disease.Medical Immunology. 2018; 20 (5): 721–30. https://doi.org/10.15789/1563-0625-2018-5-721-730. Russian.
  7. Bettelli E, Carrier Y, Gao W, Korn T, Strom T. B, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441 (7090): 235–8.
  8. Lee GR. The balance of Th17 versus Treg cells in autoimmunity. Int J Mol Sci. 2018. 19: 730. Available from: https://doi.org/10.3390/ ijms19030730.
  9. Burnstock G. Purinergic nerves. Pharmacological Reviews. 1972; 24 (3): 509–81.
  10. Kukulski F, et al. Impact of ectoenzymes on p2 and p1 receptor signaling. Adv Pharmacol. 2011; 61: 263–99. PubMed: 21586362.
  11. Virgilio FD, Sarti AC, Silva RC. Purinergic signaling, DAMPs, and inflammation. American Journal of Physiology-Cell Physiology. 2020; 318 (5): 832–5. Available from: https://doi.org/10.1152/ ajpcell.00053.2020.
  12. Faas MM, Sáez T, de Vos P. Extracellular ATP and adenosine: the yin and yang in immune responses? Mol Aspects Med. 2017; 55: 9–19. DOI: 10.1016/j.mam.2017.01.002.
  13. Vuerich M, Mukherjee S, Robson SC, Longhi MS. Control of gut inflammation by modulation of purinergic signaling. Front Immunol. 2020; 11: 1882. DOI: 10.3389/fimmu.2020.01882.
  14. Gibson DJ, Elliott L, McDermott E, Tosetto M, Keegan D, Byrne K, et al. Heightened еxpression of CD39 by regulatory T lymphocytes is associated with therapeutic remission in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 21: 2806–14.
  15. Friedman DJ, Kunzli BM, A-Rahim YI, Sevigny J, Berberat PO, Enjyoji K, et al. From the cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci USA. 2009; 106: 16788–93.
  16. Zeng J, Ning Z, Wang Y, Xiong H. Implications of CD39 in immunerelated diseases. Int Immunopharmacol. 2020; 89 (Pt A): 107055. DOI: 10.1016/j.intimp.2020.107055.
  17. Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O’Farrelly C, et al. CD39Foxp3 regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. The Journal of Immunology. 2009; 183: 7602–10.
  18. Longhi MS, Moss A, Bai A, Wu Y, Huang H, Cheifetz A, et al. Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease. PLoS ONE. 2014; 9: e87956. DOI: 10.1371/journal.pone.0087956.
  19. Fernández D, Flores-Santibáñez F, Neira J, Osorio-Barrios F, Tejón G, Nuñez S, et al. Purinergic signaling as a regulator of Th17 cell plasticity. PLoS ONE. 2016; 11: e0157889. DOI: 10.1371/ journal.pone.0157889.
  20. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood. 2007; 110 (4): 1225–32.
  21. Gibson DJ, Elliott L, McDermott E, Tosetto M, Keegan D, Byrne K, et al. Heightened expression of CD39 by regulatory T lymphocytes is associated with therapeutic remission in inflammatory bowel disease. Inflamm Bowel Dis. 2015; 21: 2806–14. DOI: 10.1097/ MIB.0000000000000566.
  22. Grant Ch R, Liberal R, Holder BS, Cardone J, Ma Y, Robson SC, et al. Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology. 2014; 59 (3): 1007–15. DOI: 10.1002/hep.26583.
  23. Louis NA, Robinson AM, MacManus CF, Karhausen J, Scully M, Colgan SP. Control of IFN-alphaA by CD73: implications for mucosal inflammation. JImmunol. 2000; 180: 4246–55. DOI: 10.4049/jimmunol.180.6.4246.
  24. Sotnikov I, Louis NA. CD73-dependent regulation of interferon alpha and interleukin-10 in the inflamed mucosa. Sci World J. 2010; 10: 2167–80. DOI: 10.1100/tsw.2010.203
  25. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5’-nucleotidase (CD73). Purinergic Signal. 2006; 351–60. DOI: 10.1007/s11302-005-5302-5.
  26. Bynoe MS, Waickman AT, Mahamed DA, Mueller C, Mills JH, Czopik A. CD73 is critical for the resolution of murine colonic inflammation. BioMed Research International. 2012, Article ID 260983, 13 pages, 2012. Available from: https://doi.org/10.1155/2012/260983.
  27. Schneider E, Rissiek A, Winzer R, Puig B, Rissiek B, Haag F, et al. Generation and function of non-cell-bound CD73 in inflammation. Frontiers in Immunology. 2019; 10, article 1729. DOI: 10.3389/ fimmu.2019.01729.
  28. Maksimow M, Lea K, Nieminen A, Kylänpää L, Aalto K, et al. Early prediction of persistent organ failure by soluble CD73 in patients with acute pancreatitis. Critical Care Medicine. 2014; 42 (12): 2556–64. DOI: 10.1097/CCM.0000000000000550.